This pattern of signaling modulation of MAPK in response to docetaxel and resveratrol was also reflected in the nuclear translocation and DNA binding of AP-1, a signaling event downstream of MAPK, as evident in the electrophoretic mobility shift assay (EMSA; Physique 4f)

This pattern of signaling modulation of MAPK in response to docetaxel and resveratrol was also reflected in the nuclear translocation and DNA binding of AP-1, a signaling event downstream of MAPK, as evident in the electrophoretic mobility shift assay (EMSA; Physique 4f). dictate the signaling environment of breast cancer cells. Docetaxel could further induce HER-2 activity in these cells, which was downregulated on resveratrol treatment. Transfection of (Z)-2-decenoic acid DN-HER-2 in SK-BR-3 cells inhibits the synergism as the transfection itself sensitizes these cells to docetaxel, leaving no role for resveratrol, whereas ectopic expression of HER-2 introduces the synergism in MDA-MB-231, the triple-negative cell range, in which the synergism was minimum, attesting the crucial role of HER-2 in suppressing the sensitivity to docetaxel. Single-agent docetaxel induced HER-2-mediated resistance to cell death, which was blocked by resveratrol. Resveratrol also downregulated docetaxel-induced activation of MAPK and Akt, survival signaling pathways downstream of HER-2. In a nutshell, this study, for the first time, establishes the role of HER-2Akt signaling axis in regulating the synergistic effect of docetaxel and resveratrol in breast cancer cells overexpressing HER-2. == Introduction == Being the most frequently diagnosed female (Z)-2-decenoic acid cancer worldwide, breast cancer is always a mystifying puzzle, owing to its highly heterogeneous and complex nature. (Z)-2-decenoic acid The molecular intricacies associated with breast cancer raise a distinctive curiosity among the researchers to unravel the mystery behind the wide contrast in responsiveness to treatments by the different subtypes of breast cancer. The expression status CDC25C of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth element receptor-2 (HER-2/neu) is highly significant in clinical scenario due to the influence of those trios in dictating the response of breast cancer cells to the currently available chemotherapeutic providers. 1, 2Hormonal receptors are ideal therapeutic targets and tumors overexpressing them usually respond well to hormonal therapy. 3On the contrary, the HER-2 overexpression is recognized as as a clinical dilemma, which often portends tumour aggressiveness and chemotherapeutic resistance in tumor cells. In 2025% of invasive breast cancers, HER-2gene is either overexpressed or amplified. 4As an epidermal growth factor receptor (EGFR), HER-2 is not known to hole with any known ligands but can heterodimerize with other related EGFR family members. By doing so, it could recruit various adaptor proteins, which in turn lead to the activation of (Z)-2-decenoic acid multiple signal transduction cascades including RAFMEKERK and PI3K/AKT/mTOR pathways. 5All these signaling events activated on HER-2 overexpression provide a pro-survival environment in breast cancer cells leading to chemotherapeutic resistance. Docetaxel, an FDA-approved taxane frequently used to get frontline therapeutic treatment of breast cancer, exerts its cytotoxicity by altering the dynamics of tubulin formation in cancer cells. 6Although (Z)-2-decenoic acid docetaxel is efficient in blocking its target, the general inefficiency of this drug to overcome the survival signals, which get activated in response to its treatment, often leads to chemotherapeutic resistance and even to tumor relapse. Multiple survival mechanisms accounting to the docetaxel resistance include enhanced activity of drug efflux pumps and increased activation of general survival signals. 7There are ample evidence regarding the activation of survival signals including the prominent kinase networks such as mitogen-activated protein kinase (MAPK) and PI3K/Akt or the transcription element such as nuclear factor-B (NF-B) and AP-1 in response to docetaxel treatment, which in turn could create a cellular pro-survival environment leading to apoptosis resistance. Chemosensitization is a good strategy to surmount such drawbacks involved in docetaxel treatment. A compound that can efficiently downregulate the survival signals activated by docetaxel can work as a chemosensitizer and can enhance its efficacy. Several pharmacologically safe phytochemicals have been reported to act because potent chemosensitizers in combination with standard chemotherapeutic drugs. 8, 9Resveratrol, a natural chemopreventive, is one among them and possesses all attractive traits such as multi-targeting efficacy, pharmacological security, immediate availability and cost effectiveness, which are required for a classic chemosensitizer. 1012The relationship between HER-2 signaling and taxane resistance are mediated through activation of PI3K/Akt and upregulation of survivin, a factor known to help the tumor cells to avoid taxane toxicity by inducing an early mitotic exit. 1316Similarly, HER-2 is shown to influence the multi-drug efflux pump activation, a crucial factor known to provide.